PRTG
Price:
$5.01
Market Cap:
$5.25M
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses o...[Read more]
Industry
Biotechnology
IPO Date
2002-01-02
Stock Exchange
NASDAQ
Ticker
PRTG
According to Portage Biotech Inc.’s latest financial reports and current stock price. The company's current ROE is -267.72%. This represents a change of 31.33% compared to the average of -203.86% of the last 4 quarters.
The mean historical ROE of Portage Biotech Inc. over the last ten years is -91.27%. The current -267.72% ROE has changed 193.34% with respect to the historical average. Over the past ten years (40 quarters), PRTG's ROE was at its highest in in the March 2018 quarter at 1.30%. The ROE was at its lowest in in the March 2024 quarter at -618.82%.
Average
-91.27%
Median
-16.38%
Minimum
-1873.17%
Maximum
1.29%
Discovering the peaks and valleys of Portage Biotech Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.60%
Maximum Annual ROE = 1.29%
Minimum Annual Increase = -149.22%
Minimum Annual ROE = -1873.17%
Year | ROE | Change |
---|---|---|
2024 | -1873.17% | 1.26% |
2023 | -137.56% | 769.82% |
2022 | -15.82% | -6.66% |
2021 | -16.94% | 125.63% |
2020 | -7.51% | 184.06% |
2019 | -2.64% | -100.21% |
2018 | 1.29% | 4.60% |
2017 | 27.35% | -149.22% |
2016 | -55.57% | -52.61% |
2015 | -117.24% | -55.50% |
The current ROE of Portage Biotech Inc. (PRTG) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-675.52%
5-year avg
-410.20%
10-year avg
-91.27%
Portage Biotech Inc.’s ROE is greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Blueprint Medicines Corporation (-47.66%), greater than Arvinas, Inc. (-50.26%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), greater than Cue Biopharma, Inc. (-142.93%), greater than Decibel Therapeutics, Inc. (-84.03%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Edgewise Therapeutics, Inc. (-28.01%), less than Harmony Biosciences Holdings, Inc. (23.16%), greater than Lineage Cell Therapeutics, Inc. (-35.54%), greater than MAIA Biotechnology, Inc. (-18051.81%), less than Armata Pharmaceuticals, Inc. (182.35%), less than Frequency Therapeutics, Inc. (187.90%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%),
Company | ROE | Market cap |
---|---|---|
-46.15% | $388.07M | |
-30.79% | $12.60B | |
-47.66% | $5.84B | |
-50.26% | $1.84B | |
-83.65% | $78.52M | |
-47.03% | $342.68M | |
-138.92% | $49.01M | |
-142.93% | $89.71M | |
-84.03% | $123.37M | |
-44.73% | $2.25B | |
-8.78% | $2.91B | |
-52.10% | $127.22M | |
-28.01% | $3.23B | |
23.16% | $1.88B | |
-35.54% | $158.36M | |
-18051.81% | $68.85M | |
182.35% | $85.03M | |
187.90% | $10.94M | |
-22.40% | $1.49B | |
-24.63% | $177.24M | |
32.93% | $89.59M | |
-68.93% | $277.29M | |
-56.92% | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Portage Biotech Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Portage Biotech Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Portage Biotech Inc.'s ROE?
How is the ROE calculated for Portage Biotech Inc. (PRTG)?
What is the highest ROE for Portage Biotech Inc. (PRTG)?
What is the 3-year average ROE for Portage Biotech Inc. (PRTG)?
What is the 5-year average ROE for Portage Biotech Inc. (PRTG)?
How does the current ROE for Portage Biotech Inc. (PRTG) compare to its historical average?